IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation
Jung Won ParkiD, Jiehoon KwakiD, Keon Woo KimiD, Saehoon JungiD, Chang Hyun NamiD, Hyun Jung KimiD, Sang Mee LeeiD, Chanho Choi, Yongjin AhniD, Ji‐Hyung ParkiD, Jihwan YooiD, Jin‐Kyoung ShimiD, Hye Joung ChoiD, Eui-hyun KimiD, Chungyeul KimiD, Sangjeong AhniD, Stefan PuschiD, Andreas von DeimlingiD, Jong Hee ChangiD, Se Hoon KimiD, Hoon KimiD, Young Seok JuiD, Kang SsiD, Jeong Ho LeeiD
Abstract
Discovering the cell-of-origin harboring the initial driver mutation provides a fundamental basis for understanding tumor evolution and development of new treatments. For isocitrate dehydrogenase (IDH)-mutant gliomas - the most common malignant primary brain tumors in adults under 50 - the cell-of-origin remains poorly understood. Here, using patient brain tissues and genome-edited mice, we identified glial progenitor cells (GPCs), including oligodendrocyte progenitor cells (OPCs), as the glioma-originating cell type harboring the IDH mutation as the initial driver mutation. We conducted comprehensive deep sequencing, including droplet digital PCR and deep panel and amplicon sequencing to 128 tissues from 62 patients (29 IDH-mutant gliomas and 33 IDH-negative controls) comprising tumors, normal cortex or normal subventricular zone (SVZ), and blood. Surprisingly, low-level IDH mutation was found in the normal cortex away from the tumor in 38.5% (10 of 26) of IDH-mutant glioma patients, whereas no IDH mutation was detected in the normal SVZ. Furthermore, by analyzing cell-type-specific mutations, the direction of clonal evolution, the single-cell transcriptome from patient brains and novel mouse model of IDH-mutant glioma arising from mutation-carrying OPCs, we determined that GPCs, including OPCs, harboring the initial driver mutation are responsible for the development and evolution of IDH-mutant gliomas. In summary, our results demonstrate that GPCs containing the IDH mutation are the cells-of-origin harboring the initial driver mutation in IDH-mutant gliomas.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 23
- FWCI
- 83.64
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mutant IDH silences GSX2 to reprogram neural progenitor cell fate and promote gliomagenesis
Yi Xiao, Diana D. Shi, … Samuel K. McBrayer·bioRxiv·Aug 12, 2025
- Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas
Tamrin Chowdhury, C. Mircea S. Tesileanu, … Roel G.W. Verhaak·bioRxiv·Jul 11, 2025
- Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell cultures
C. Verheul, I. Ntafoulis, … M. Lamfers·bioRxiv·Apr 9, 2021
- Immune Contexture of Isocitrate Dehydrogenase stratified Human Gliomas
P. Gupta, M. Dang, … K. P. Bhat·bioRxiv·Nov 8, 2022
- The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen
Tathiane Maistro Malta, Thaís S. Sabedot, … Peter S. LaViolette·Cancer ResearchPeer-reviewed·Dec 20, 2023
- Spatially confined niches support hypoxia-associated transcriptional plasticity contributing to malignant progression in IDH-mutant gliomas
Depro Das, Alina Pandele, … Sajib Chakraborty·bioRxiv·Jun 3, 2026